Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

US10501440B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Sara Frattini · Castelleone, IT
• Iain Lingard · Monza, IT
• Dieter Hamprecht · Verona, IT
• Remko Alexander BAKKER · Biberach an der Riß, DE
• Matthias Eckhardt · Hannover, DE
• Andreas Gollner · Wien, AT
• Joerg P. Hehn · Biberach an der Riß, DE
• Elke Langkopf · Biberach an der Riß, DE
• Holger Wagner · Mettenberg, DE
• Bernd Wellenzohn · Friedrichshafen, DE
• Dieter Wiedenmayer · Biberach an der Riß, DE

Key dates

• Filing date: Apr 16, 2018
• Grant date: Dec 10, 2019
• Expiry date: Apr 16, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P3/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.